CJC-1295 DAC (2mg)


CJC-1295 peptide, also known as modified growth releasing factor amino acids 1-29 and CJC-1295 without DAC, is a synthetic mimic of a portion of naturally produced growth hormone releasing hormone (GHRH). The CJC peptide chemistry is based around the first 29 building blocks of endogenously produced GHRH as these first 29 amino acids provide full biological activity [1]. GHRH is necessary for natural growth hormone secretion and is also needed to achieve optimal natural growth during development [2]. CJC-1295 works by stimulating growth hormone secretion by binding to GHRH receptors and should stimulate the secretion of the whole family of growth hormone peptides normally secreted by the pituitary gland [2]. These hormones will stimulate increases in bone density and collagen production, as well as boosting the immune system. They will also stimulate the production of lean muscle mass. CJC-1295 can be combined with another peptide-based growth hormone stimulator called ipamorelin for enhanced results. Combined use of CJC-1295 and ipamorelin will accelerate fat loss and weight loss and stimulate anabolic effects via growth hormone induced fat breakdown [3]. Overall, CJC-1295 will stimulate protein synthesis and fuel the growth of lean muscle tissue. The peptide also promotes faster injury recovery, a reduction in body fat and increased muscle mass. The growth stimulatory properties of CJC-1295 will also stimulate cell growth and division to improve skin health, healing and immune system function [4, 5]. This peptide should not be confused with CJC-1295 with DAC as the chemical properties are very different and will affect dosing. CJC-1295 (without DAC) is fast acting and has a half-life of around 10-12 minutes following injection [3]. CJC-1295 injections should be subcutaneous and the peptide can be injected two or three times per day at doses of 100 mcg or 200 mcg. CJC-129 should be administered on waking, following a workout and before sleep to mimic the natural, pulsed release of natural growth hormone throughout the day. Many researchers have documented the growth-promoting effects and safety of GHRH administered to children with growth hormone deficiency [6, 7]. Multiple treatment regimes, including intravenous pulses, intranasal delivery, subcutaneous injections, and continuous infusion have been tested to show that the growth-promoting effect of GHRH is connected with the dose amount and frequency. No unexpected adverse reactions have been seen after prolonged treatment, regardless of the mode of administration [8, 9]. However, some minor side effects may occur, including tiredness, euphoria (head rush), water retention, tingling and numbness. Following the recommended dosage will minimise the risk of side effects. References 1. Lance, V.A., et al., Super-active analogs of growth hormone-releasing factor (1-29)-amide. Biochem Biophys Res Commun, 1984. 119(1): p. 265-72. 2. Ionescu, M. and L.A. Frohman, Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. The Journal of Clinical Endocrinology & Metabolism, 2006. 91(12): p. 4792-4797. 3. Kim, K.R., et al., Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults. Horm Res, 1999. 51(2): p. 78-84. 4. Koo, G.C., et al., Immune Enhancing Effect of a Growth Hormone Secretagogue. The Journal of Immunology, 2001. 166(6): p. 4195-4201. 5. Dioufa, N., et al., Acceleration of wound healing by growth hormone-releasing hormone and its agonists. Proceedings of the National Academy of Sciences of the United States of America, 2010. 107(43): p. 18611-18615. 6. Rochiccioli, P.E., et al., Results of 1-year growth hormone (GH)-releasing hormone-(1-44) treatment on growth, somatomedin-C, and 24-hour GH secretion in six children with partial GH deficiency. J Clin Endocrinol Metab, 1987. 65(2): p. 268-74. 7. Low, L.C., et al., Long term pulsatile growth hormone (GH)-releasing hormone therapy in children with GH deficiency. J Clin Endocrinol Metab, 1988. 66(3): p. 611-7. 8. Khorram, O., et al., Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women. J Clin Endocrinol Metab, 1997. 82(11): p. 3590-6. 9. Neyzi, O., et al., Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone. Acta Paediatr Suppl, 1993. 388: p. 16-21; discussion 22.

  • Return and Refund Policy

    this is my return and refund policy





© 2020 by Research Peptides UK